Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene

Blood

Volumn 115, Issue 6, 2010, Pages 1264-1266

  Paterson, Andrew D ^a,b   Rommens, Johanna M ^a,c   Bharaj, Bhupinder ^a   Blavignac, Jessica ^d   Wong, Isidro ^a   Diamandis, Maria ^d   Waye, John S ^d   Rivard, Georges E ^e   Hayward, Catherine P M ^d,f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLAU PROTEIN; UNCLASSIFIED DRUG; UROKINASE;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FAMILY; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUEBEC PLATELET DISORDER; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE DISORDER; BLOOD; CHROMOSOME 10; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENETICS; KARYOTYPING; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROGNOSIS; SEQUENCE HOMOLOGY;

ADULT; BASE SEQUENCE; BLOOD PLATELET DISORDERS; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; GENE DOSAGE; GENE DUPLICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MOLECULAR SEQUENCE DATA; PROGNOSIS; SEQUENCE HOMOLOGY, NUCLEIC ACID; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77949516918     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-233965     Document Type: Article

References (20)

1. Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrinolysis. 2008;19(2):109-119.
2. Diamandis M, Adam F, Kahr WH, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost. 2006;4(5):1086-1094.
3. McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood. 2004;104(1):159-165. (Pubitemid 38879852)
4. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood. 2001;98(2):257-265.
5. Veljkovic DK, Rivard GE, Diamandis M, et al. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood. 2009;113(7):1535-1542.
6. Diamandis M, Veljkovic DK, Derome F, Rivard GE, Hayward CPM. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. Blood Coagul Fibrinolysis. 2008;19(5):463-464.
7. Sheth PM, Kahr WH, Haq MA, et al. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost. 2003;90(2):293-298.
8. Hayward CP, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood. 1996;87(12):4967-4978. (Pubitemid 26189838)
9. Hayward CP, Cramer EM, Kane WH, et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the α-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to α-granules. Blood. 1997;89(4):1243-1253.
10. Hayward CP, Welch B, Bouchard M, Zheng S, Rivard GE. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br J Haematol. 1997;97(2):497-503. (Pubitemid 27224639)
11. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood. 1996;87(9):3571-3578.
12. Diamandis M, Paterson AD, Rommens JM, et al. Quebec platelet disorder is linked to the plasminogen activator gene (PLAU) and increases the expression of the linked PLAU allele in megakaryocytes. Blood. 2009;113(7):1543-1546.
13. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinasetype plasminogen activator in platelets. Blood. 2003;102(3):926-933. (Pubitemid 36917785)
14. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.
15. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21(13):2933-2942. (Pubitemid 40916416)
16. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA. Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet. 2008;40(10):1199-1203.
17. McCarroll SA, Kuruvilla FG, Korn JM, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40(10):1166-1174.
18. Tanaka M, Kirito K, Kashii Y, et al. Forkhead family transcription factor FKHRL1 is expressed in human megakaryocytes: regulation of cell cycling as a downstream molecule of thrombopoietin signaling. J Biol Chem. 2001;276(18):15082-15089. (Pubitemid 37373393)
19. Kirito K, Kaushansky K. Transcriptional regulation of megakaryopoiesis: thrombopoietin signaling and nuclear factors. Curr Opin Hematol. 2006;13(3):151-156. (Pubitemid 43755854)
20. Minamiguchi H, Kimura T, Urata Y, et al. Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC and MAPK pathways. Br J Haematol. 2001;115(1):175-185. (Pubitemid 32995114)